UK firms welcome new price increase deal:
This article was originally published in Clinica
Executive Summary
Companies in the UK have welcomed the introduction of a new mechanism for establishing annual price increases for healthcare products prescribed by GPs and reimbursed by the government. Under an agreement with the Department of Health's Drug Tariff Section, companies will use a formula for establishing the maximum available price increase for products such as glucose testing strips and hypodermic syringes and needles. The formula consists of the "GDP deflator", which is currently 2.75%, minus an agreed "efficiency deduction" of 0.75%. The Association of British Health-Care Industries comments that this is the first time it has had a dedicated group lobby for a price increase. The agreement, which will be reviewed after three years, covers products listed under part IX of the Drug Tariff.
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.